Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9883952 | 0.84 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KDM4EHTTLMNA | |
| SCHEMBL16656263 | 0.83 | KDM4E (0.56) | ALDH1A1SMN1; SMN2KDM4EHTTLMNA | |
| SCHEMBL12195291 | 0.83 | KDM4E (0.56) | ALDH1A1SMN1; SMN2KDM4EHTTLMNA | |
| SCHEMBL18412521 | 0.81 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2KDM4EHTTLMNA | |
| SCHEMBL18412519 | 0.80 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2KDM4EHTTLMNA | |
| SCHEMBL18412520 | 0.79 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2KDM4EHTTLMNA | |
| SCHEMBL14312189 | 0.78 | KDM4E (0.50) | ALDH1A1SMN1; SMN2KDM4EHTTLMNA | |
| SCHEMBL17152939 | 0.77 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2KDM4EHTTLMNA | |
| SCHEMBL13558227 | 0.77 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2KDM4EHTTLMNA | |
| SCHEMBL31584076 | 0.76 | BCL9 (0.52) | ALDH1A1SMN1; SMN2KDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119103-B2 | Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates | MALLINCKRODT LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119103-B2 | Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates | MALLINCKRODT LLC (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090082324-A1 | Bifunctional Resorcinol, Thioresorcinol, and Dithioresorcinol Derivative Metal Chelating Conjugates | INFACARE PHARMACEUTICAL CORPORATION | 2009-03-26 | — | — | US | disclosed |
| US-20090082324-A1 | Bifunctional Resorcinol, Thioresorcinol, and Dithioresorcinol Derivative Metal Chelating Conjugates | INFACARE PHARMACEUTICAL CORPORATION | 2009-03-26 | — | — | US | disclosed |
| WO-2007100563-A2 | BIFUNCTIONAL RESORCINOL, THIORESORCINOL, AND DITHIORESORCINOL DERIVATIVE METAL CHELATING CONJUGATES | MALLINCKRODT INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082324-A1 | Bifunctional Resorcinol, Thioresorcinol, and Dithioresorcinol Derivative Metal Chelating Conjugates | SPR, QDPR, SLC40A1 | ALDH1A1 716/4885SMN1; SMN2 3974/4885KDM4E 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.